Salmaan Keshavjee, MD, PhD
About Salmaan Keshavjee, MD, PhD
Salmaan Keshavjee, MD, Ph.D, MA, Sc.M, is the Director of the Program in Infectious Disease and Social Change at the Department of Global Health and Social Medicine (DGHSM) at Harvard Medical School. Trained as a physician and social anthropologist, Dr. Keshavjee is an Assistant Professor of Medicine and Social Medicine at Harvard Medical School and in the Division of Global Health Equity at Brigham and Women’s Hospital. He is also an attending in Internal Medicine at Brigham and Women’s Hospital. Dr. Keshavjee completed his thesis work in Harvard’s Department of Anthropology and Center for Middle Eastern Studies on health policies in post-Soviet Tajikistan. Dr. Keshavjee’s clinical research has focused on the implementation of drug-resistant tuberculosis treatment projects run by Partners In Health, and associated treatment outcomes. He has worked extensively with PIH’s drug-resistant tuberculosis program in Russia since 2000. From 2006 to 2008, he was Deputy Country Director for the PIH Lesotho Initiative, launching one of the first community-based treatment programs for multi-drug resistant tuberculosis/HIV co-infection in sub-Saharan Africa. Since 2007 he has led PIH’s Russia research initiative, coordinating a multi-disciplinary team studying treatment outcomes in drug-resistant tuberculosis. This work is informing efforts to treat drug-resistant tuberculosis in the region, including Central Asia, and has resulted in several manuscripts of global clinical and policy significance. Starting in 2005, Dr. Keshavjee has represented PIH/Harvard on the Green Light Committee (GLC) for multi-drug resistant tuberculosis, the principal global mechanism for MDR-TB treatment expansion, housed at the Stop TB Partnership and the World Health Organization. From 2007 until September, 2010, he served as the Committee’s Chair. Through his roles at Harvard, PIH and the GLC, he has advised numerous national programs on the clinical and programmatic management of MDR-TB.
(Source: http://www.brighamandwomens.org/socialmedicine/keshavjeebio.aspx)
Role(s) / Profession(s)
- Academic
- Director (Site, Program, Project)
- Physician
- Researcher
Organization
- Brigham and Women's Hospital, Division of Global Health Equity
- Harvard Medical School, Department of Global Health and Social Medicine
- Partners In Health - PIH
Work Location(s)
- Russian Federation
- United States
Salmaan's Communities
Language(s)
- English
Recent Contributions
-

Salmaan Keshavjee, MD, PhD started a discussion "3rd Stop TB Partners’ Forum Announced: March 23-25, 2009" in the MDR-TB Treatment & Prevention community.
The Stop TB Partnership Secretariat announced that the third Partner's Forum will take place in Rio de Janeiro, Brazil, March 23-25, 2009. The Forum serves as a vehicle for bringing partners together to renew their commitment and intensify their efforts to reach the targets set out in the Global Plan to Stop TB 2006-2015. What is the Stop TB Partners' Forum: The Partners' Forum is the General Assembly of the Stop TB Partnership and the ...
-

Salmaan Keshavjee, MD, PhD replied to "Question about treatment outcome" in the MDR-TB Treatment & Prevention community.
Dear Mamel, I tend to agree with Einar on this. The clinical question and the reporting question are different. Clinically, it sounds like he should not do another whole treatment. Personally, I would do 6 to 10 more months and ensure that he remains negative the whole time. This way, he'll have a total of 20 to 24 months of total treatment (with the gap of 2 months). As for his outcome, unfortunately for paper-work ...
-

Salmaan Keshavjee, MD, PhD replied to "Question about Sparflox" in the MDR-TB Treatment & Prevention community.
Hi Askar, Sparfloxacin was removed from the U.S. market because of QT-interval prolongation and increased risk of heart arrhythmias. So, I think it's not a good idea to use it if you have another choice. If using moxifloxacin is a problem, you might consider using high-dose levoquin (750 mg for people weighing less than 50 kg; 1000 mg for people weighing more than 50 kg). This is the dosing that the Iseman's group in Denver ...
-

Salmaan Keshavjee, MD, PhD replied to "Question about treatment outcome" in the MDR-TB Treatment & Prevention community.
I know it's frustrating Mamel, but unfortunately, these things happen. We can be happy as clinicians knowing in our hearts that the pt is cured, but unfortunately it doesn't make sense to deviate from the standardized reporting. We have this argument frequently in Russia, but have stuck by the WHO reporting.
-

Salmaan Keshavjee, MD, PhD replied to "Universal Access to Diagnosis and Treatment of MDR-TB" in the MDR-TB Treatment & Prevention community.
Dear Masoud, All, Indeed, achieving universal access to diagnosis and treatment of MDR-TB is critical, and for that we need to scale-up access to quality diagnosis and treatment of MDR. From our combined experiences, Paul Farmer and I recently made the case for this in the NEJM, “Picking Up the Pace – Scale-up of MDR Tuberculosis Treatment Programs” (full text here: http://www.nejm.org/doi/full/10.1056/NEJMp1010023). In this piece, we estimated that treatment of MDR-TB has been abysmal – ...
Recent Recommendations
- None at this time.
